“showed a trend”

Although RMT also showed a trend toward improved quality of life (SMD 1.00, 95% CI 0.00-1.99; P = .05), this result was borderline significant and derived from only three studies and should therefore be interpreted cautiously.

While E2 levels in the Ctr-T group showed a trend toward lower levels than the Sham group, this difference was not statistically significant ( P > 0.05).

Therefore, although the results for the topical test showed a trend of anti-inflammatory action, they were not significant ( p < 0.05).

Notably, serum Nrf-2 levels in the EtOH group showed a trend toward elevation without significant change ( p > 0.05), whereas GPX4 levels exhibited a trend toward reduction without significant change ( p > 0.05).

Similarly, the area under the curve (AUC) of the 3 mg/kg or 10 mg/kg ciclamilast-treated and the 0.1 mg/kg MTX-treated groups also showed a trend toward less paw edema compared with the vehicle-treated rats (each P < 0.05 or 0.01) ( Figure 1 ). 3.2.

In addition, they showed a trend effect for up-regulation of genes implicated in GABA synthesis: GLS (p = 0.050) and GAD1 (p = 0.050) and significant down-regulation of ABAT (p = 0.030) that plays a role in GABA metabolism.

Furthermore, HIV‐1‐infected males with an increased cIMT showed a trend toward an upregulation of ISG56 and a deregulation of IFN‐α mRNA expression (Figure 3A,C ; p > .05), compared to those with a cIMT <0.9 mm. 4.

Although the SAH + B12 group showed a trend toward increased luminal diameter and reduced wall thickness compared to the SAH group, these differences did not reach statistical significance ( p > 0.05).

Furthermore, out of the suggested loci found to be promising candidates for the antidepressant response in clinical applications after validation 34 , multiple SNPs at ABCB1, BDNF, CYP2C19, SLC6A2, CYP2D6 , and HTR2A showed a trend for influencing antidepressant response at a nominal significance in our study ( P < 0.05) (Table S17 ).

34%, P = 0.002), although the latter also showed a trend of increased mortality compared with Ubi-A10/+ controls (34 vs. 8%, P = 0.05).

Notably, the Nrf2/HO-1 expression levels showed a trend toward upregulation in the SCI group compared with the Sham group (P>0.05), suggesting a possible endogenous compensatory response to injury-associated oxidative stress.

Of the 12 correlation analyses performed, 3 were nominally significant ( p < 0.05) and another 2 showed a trend ( p < 0.1).

RT-qPCR analysis showed a trend for increased miR-141 expression and decreased FOXC1 expression in HGC27 cells in response to si-LINC00242 transfection ( p < 0.05) (Fig. 3 k).

All patients showed a trend to lower blood pressure, SVR, and inotropy (P<0.05), but HR, SV, and CO returned to baseline values after 6 weeks treatment (P>0.05).

In direct comparisons between the active treatment groups, combined therapy showed a trend toward lower mortality compared with aspirin monotherapy at 28 days (HR 0.52, 95% CI: 0.27-1.00, P = 0.05), with significant benefit at 90 days (HR: 0.47, 95% CI: 0.27-0.83, P < 0.01) and 1 year (HR: 0.59, 95% CI: 0.39-0.91, P = 0.02).

Although not passing the strict multiple-testing correction threshold ( P < .005), in the negative control analyses (ie, paternal dyads) (eTable 9 in Supplement 2 ), paternal allele scores showed a trend of positive associations with various offspring NDDs ( P < .05; F1 and SCQ-full at 8 years: β = 1.99E-03, SE = 8.75E-04; M2 and SCQ-RRB at 8 years: β = 3.65E-03, SE = 1.32E-03; M3 and SCQ-RRB at 8 years: β = 5.50E-03, SE = 2.02E-03; F1 and SCQ-SCI at 8 years: β = 2.02E-03, SE = 8.64E-04; M2 and ASQ-LANG at 3 years: β = 2.05E-03, SE = 1.15E-03; and M2 and Children's Communication Checklist–Short Scale at 8 years: β = 3.35E-03, SE = 1.63E-03).

2.6 ± 0.2 g on HFD; main effect p < 0.05), while adipose tissue showed a trend for lower values (1.0 ± 0.2 vs. 1.3 ± 0.1 g on STD; 2.5 ± 0.2 vs. 2.7 ± 0.2 g on HFD; p > 0.05) (Fig. 1E, F ).

Urinary Hg showed a trend of decrease ( p < 0.05) with increasing pre-pregnancy BMI.

In subgroup analysis, hypertensive patients with high MDA were significantly older ( p = 0.03) and showed a trend towards higher systolic BP ( p = 0.05) compared to those with low MDA.

Similarly, in the Pembrolizumab + Docetaxel group, non-responders showed a trend towards increased EV PD-L1 in comparison to responders ( p = 0.050) (Fig. 3 E) while no differences were observed in the Docetaxel treated patients (Fig. 3 F).

Individuals carrying a genotype with the variant C at rs1360485 showed a trend for reduced expression of HMGB1, compared with the wild-type homozygous genotypes ( p < 0.05, Figure 1 ).

Compared to the negative control, the fluorescent intensity of activated caspase-3 in A549 cells showed a trend of enhancing (15.50 ± 0.89 vs 15.50 ± 0.89 at 15 μM, p > 0.05; 18.43 ± 1.19 vs 15.50 ± 0.89 at 30 μM, p < 0.05; 22.90 ± 1.54 vs 15.50 ± 0.89 at 75 μM, p < 0.01; 42.83 ± 3.15 vs 15.50 ± 0.89 at 300 μM, p < 0.01) (Figures 6 A and 6 B).

While the total number of births for each year showed a trend of continuous significant decrease, the rate of pregnancies of advanced age (35 years or greater) exhibited a trend of significant increase, from 9.5% in 1992 to 26.2% in 2022 (p-value < 0.001); but, surprisingly, the percentage of pregnancies with extremely advanced age was relatively constant, at 0.1–0.3%, throughout the 30 year-period of the study, not showing a significant trend (p-value > 0.05).

In the second period, the effect of rapport building was not significant, but showed a trend ( B = 0.011, Z = 1.96, p = .05).

While PPRH2 showed a trend toward greater single-agent activity, these differences were statistically significant only when comparing DOTAP to PPRH2 ( p < 0.05) and Sc9 to PPRH2 ( p < 0.01) ( Figure 3 A), indicating that this concentration was appropriately sub-cytotoxic for combination studies.